AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22559159 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy + Amlodipine (calcium channel blocker)
Number of subjects: 0
Study 22559159 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy + Valsartan (angiotensin receptor blocker)
Number of subjects: 0
Study 19712037 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoster vaccine
Number of subjects: 981
Study 19712037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 981
Study 19712037 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoster vaccine and HZ
Number of subjects: 981
Study 17726086 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (200 mg im every other week for 90 days)
Number of subjects: 15
Study 17726086 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sesame oil vehicle im)
Number of subjects: 15
Study 17726086 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate
Number of subjects: 15
Study 15894768 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg/day)
Number of subjects: 50
Study 15894768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 12503776 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 5 mg/day
Number of subjects: 110
Study 12503776 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 10 mg/day
Number of subjects: 110
Study 12503776 — intervention group
Group type: COMPARATOR
Intervention: Octa-60 5 mg/day
Number of subjects: 110
Study 12503776 — intervention group
Group type: COMPARATOR
Intervention: Octa-60 10 mg/day
Number of subjects: 110
Study 9583201 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycated Hemoglobin (GHb)
Number of subjects: 26
Study 9583201 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructosamine (Frc)
Number of subjects: 26
Study 9583201 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting Blood Glucose (FBG)
Number of subjects: 26
Study 9583201 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial White Blood Cell (WBC) count
Number of subjects: 26
Study 9583201 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia during induction therapy
Number of subjects: 26
Study 9583201 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of diabetes mellitus
Number of subjects: 26
Study 7535267 — intervention group
Group type: EXPERIMENTAL
Intervention: Process-oriented treatment (POR chi) approach
Number of subjects: 75
Study 7535267 — intervention group
Group type: COMPARATOR
Intervention: Traditional or general motor approach
Number of subjects: 75
Study 7535267 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 75
Study 1626663 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol target concentration of 3 micrograms.ml‐1
Number of subjects: 60
Study 1626663 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol target concentration of 4 micrograms.ml‐1
Number of subjects: 60
Study 1626663 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol target concentration of 5 micrograms.ml‐1
Number of subjects: 60
Study 1626663 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol target concentrations (3, 4, 5 micrograms.ml‐1)
Number of subjects: 60
Study 6334937 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrotherapy using the Tenzcare Nr. 6240 apparatus
Number of subjects: 0
Study 29130400 — intervention group
Group type: EXPERIMENTAL
Intervention: EBCT-R (Exposure-Based Cognitive Therapy for depression)
Number of subjects: 149
Study 29130400 — intervention group
Group type: COMPARATOR
Intervention: CBT (Cognitive Behavioral Therapy)
Number of subjects: 149
Study 29130400 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EBCT-R and CBT
Number of subjects: 149
Study 30509345 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery
Number of subjects: 0
Study 30509345 — intervention group
Group type: COMPARATOR
Intervention: Traditional radiation therapy
Number of subjects: 0
Study 26450911 — intervention group
Group type: COMPARATOR
Intervention: Treadmill walking with preferred walking speed (TPWS)
Number of subjects: 2
Study 26450911 — intervention group
Group type: COMPARATOR
Intervention: Floor walking with preferred walking speed (FPWS)
Number of subjects: 2
Study 24764581 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DPB1*04 (DP04)-binding NY-ESO-1157-170 peptide vaccination
Number of subjects: 0
Study 24764581 — intervention group
Group type: EXPERIMENTAL
Intervention: Short 8-9-mer peptides
Number of subjects: 0
Study 24764581 — intervention group
Group type: COMPARATOR
Intervention: Primaquine (inhibitor of endosomal recycling)
Number of subjects: 0
Study 23254461 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized Korean ginseng berry (SKGB, 350 mg ginseng berry extract per tablet)
Number of subjects: 119
Study 20585867 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiochemotherapy (5‐FU, cisplatin, 36 Gy)
Number of subjects: 297
Study 20585867 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 297
Study 17846813 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 33
Study 16801310 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleotide supplemented formula (FN)
Number of subjects: 21
Study 16801310 — intervention group
Group type: COMPARATOR
Intervention: Regular formula (RF)
Number of subjects: 21
Study 16801310 — intervention group
Group type: COMPARATOR
Intervention: Breast-fed newborns (C)
Number of subjects: 21
Study 14584060 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 0
Study 14584060 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study 10915847 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR‐SSP method for genotyping MBL mutations
Number of subjects: 100
Study 10915847 — intervention group
Group type: EXPERIMENTAL
Intervention: HY haplotype
Number of subjects: 100
Study 10915847 — intervention group
Group type: EXPERIMENTAL
Intervention: LY haplotype
Number of subjects: 100
Study 10915847 — intervention group
Group type: EXPERIMENTAL
Intervention: LX haplotype
Number of subjects: 100
Study 10915847 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural variants B, C, and D
Number of subjects: 100
Study 9264489 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral Regurgitation (MR) present
Number of subjects: 727
Study 9264489 — intervention group
Group type: COMPARATOR
Intervention: No Mitral Regurgitation (MR)
Number of subjects: 727
Study 8261826 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal administration of 1 g/hr of fat
Number of subjects: 6
Study 8261826 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal administration of 2 g/hr of fat
Number of subjects: 6
Study 8261826 — intervention group
Group type: COMPARATOR
Intervention: Hyperglycemia
Number of subjects: 6
Study 3577269 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (rehabilitation patients)
Number of subjects: 110
Study 3577269 — intervention group
Group type: COMPARATOR
Intervention: Group A (control group)
Number of subjects: 110
Study 29182458 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced consent procedure (multimedia disclosure and corrective feedback)
Number of subjects: 248
Study 29182458 — intervention group
Group type: COMPARATOR
Intervention: Routine consent
Number of subjects: 248
Study 27376872 — intervention group
Group type: EXPERIMENTAL
Intervention: RTG/EZG 600 mg/day
Number of subjects: 76
Study 27376872 — intervention group
Group type: EXPERIMENTAL
Intervention: RTG/EZG 900 mg/day
Number of subjects: 76
Study 27376872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 25363099 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B1
Number of subjects: 80
Study 25363099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 22292673 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic (IT) steroid and hyperbaric oxygen (HBO) therapy
Number of subjects: 48
Study 22292673 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) steroid and hyperbaric oxygen (HBO) therapy
Number of subjects: 48
Study 20038718 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17714541 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasteurized own mother's milk
Number of subjects: 2
Study 17714541 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw own mother's milk
Number of subjects: 2
Study 15647927 — intervention group
Group type: EXPERIMENTAL
Intervention: APC8015 (Provenge) - an investigational therapeutic vaccine using autologous antigen presenting cells (APCs) loaded with a recombinant fusion protein of prostatic acid phosphatase.
Number of subjects: 0
Study 12141813 — intervention group
Group type: EXPERIMENTAL
Intervention: GSAS (Gastroesophageal Reflux Disease Symptom Assessment Scale)
Number of subjects: 187
Study 12141813 — intervention group
Group type: EXPERIMENTAL
Intervention: SF‐36 Health Survey
Number of subjects: 187
Study 12141813 — intervention group
Group type: EXPERIMENTAL
Intervention: GSAS and SF‐36 scales
Number of subjects: 187
Study 8162730 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium (2 puffs via MDI; 36 micrograms)
Number of subjects: 48
Study 8162730 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of albuterol and theophylline
Number of subjects: 48
Study 8162730 — intervention group
Group type: EXPERIMENTAL
Intervention: All three drugs (ipratropium, theophylline, and albuterol)
Number of subjects: 48
Study 8162730 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment groups
Number of subjects: 48
Study 8162730 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline and albuterol
Number of subjects: 48
Study 3065739 — intervention group
Group type: COMPARATOR
Intervention: prednisolone (PRD) plus chlorambucil (CLB) 5 days every 4 weeks
Number of subjects: 144
Study 3065739 — intervention group
Group type: EXPERIMENTAL
Intervention: monthly intensive CHOP treatment
Number of subjects: 144
Study 3065739 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 144
Study 31199458 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D2 (2.5 mg, total of four oral bolus doses over four months)
Number of subjects: 52
Study 31199458 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2.5 mg, total of four oral bolus doses over four months)
Number of subjects: 52
Study 27463071 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated training group (ITG) - RMT using an incentive respiratory spirometer (IRS) and the abdominal drawing-in maneuver (ADIM)
Number of subjects: 37
Study 27463071 — intervention group
Group type: EXPERIMENTAL
Intervention: RMT group (RMTG) - RMT using an IRS
Number of subjects: 37
Study 27463071 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - alternative and routine physical therapy or usual care
Number of subjects: 37
Study 24850703 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphala mouth rinse (aqueous)
Number of subjects: 60
Study 24850703 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine
Number of subjects: 60
Study 24001084 — intervention group
Group type: EXPERIMENTAL
Intervention: fosphenytoin (fPHT)
Number of subjects: 795
Study 24001084 — intervention group
Group type: EXPERIMENTAL
Intervention: levetiracetam (LVT)
Number of subjects: 795
Study 24001084 — intervention group
Group type: EXPERIMENTAL
Intervention: valproic acid (VPA)
Number of subjects: 795
Study 21574708 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapse (smoking two cigarettes of their favored brand during a 30-min period)
Number of subjects: 63
Study 21574708 — intervention group
Group type: COMPARATOR
Intervention: No lapse (a no-smoking control/30-min waiting period)
Number of subjects: 63
Study 19336365 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborn Individualized Developmental Care and Assessment Program
Number of subjects: 164
Study 19336365 — intervention group
Group type: COMPARATOR
Intervention: Basic developmental care
Number of subjects: 164
Study 16633798 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 23
Study 16633798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 15286526 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention (WINS trial)
Number of subjects: 277
Study 15286526 — intervention group
Group type: EXPERIMENTAL
Intervention: Home healthcare by nurse or home health aide
Number of subjects: 277
Study 15286526 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation program (Multifit and Heart Smart)
Number of subjects: 277
Study 15286526 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 277
Study 15286526 — intervention group
Group type: EXPERIMENTAL
Intervention: Total monthly cost per woman
Number of subjects: 277
Study 15286526 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital admissions and physician and emergency-room visits
Number of subjects: 277
Study 15286526 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary prevention services
Number of subjects: 277
Study 11408853 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglactin 910 mesh
Number of subjects: 161
Study 11408853 — intervention group
Group type: COMPARATOR
Intervention: No mesh
Number of subjects: 161
Study 8989344 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/d oral phylloquinone
Number of subjects: 42
Study 8989344 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/d oral phylloquinone
Number of subjects: 42
Study 8989344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 8515098 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (600 mg) plus ethambutol (25 mg/kg) plus ciprofloxacin (750 mg)
Number of subjects: 19
Study 8515098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 2971562 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (0.125 mg) inhaled
Number of subjects: 13
Study 2971562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 2971562 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug, seated position)
Number of subjects: 13
Study 31162803 — intervention group
Group type: COMPARATOR
Intervention: Nut consumption <1 time/week
Number of subjects: 23915
Study 31162803 — intervention group
Group type: EXPERIMENTAL
Intervention: Nut consumption 1 time/week
Number of subjects: 23915
Study 31162803 — intervention group
Group type: EXPERIMENTAL
Intervention: Nut consumption 2-3 times/week
Number of subjects: 23915
Study 31162803 — intervention group
Group type: EXPERIMENTAL
Intervention: Nut consumption ≥4 times/week
Number of subjects: 23915
Study 27422249 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 1044
Study 27422249 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 1044
Study 25174991 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week supervised exercise training programme (4 sessions per week)
Number of subjects: 39
Study 24084327 — intervention group
Group type: EXPERIMENTAL
Intervention: GEN tacrolimus
Number of subjects: 126
Study 24084327 — intervention group
Group type: COMPARATOR
Intervention: REF tacrolimus
Number of subjects: 126
Study 22931614 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 255
Study 22931614 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanshinone
Number of subjects: 255
Study 22931614 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin + Tanshinone
Number of subjects: 255
Study 19514614 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan 50 mg once daily (in CORD IA)
Number of subjects: 4016
Study 19514614 — intervention group
Group type: COMPARATOR
Intervention: ramipril 5 mg (n = 1,926)
Number of subjects: 4016
Study 19514614 — intervention group
Group type: COMPARATOR
Intervention: losartan 50 mg (n = 1,887)
Number of subjects: 4016
Study 19514614 — intervention group
Group type: COMPARATOR
Intervention: ramipril and losartan (CORD IB)
Number of subjects: 4016
Study 19514614 — intervention group
Group type: COMPARATOR
Intervention: ramipril
Number of subjects: 4016
Study 17463115 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-navigated total knee replacement
Number of subjects: 71
Study 17463115 — intervention group
Group type: COMPARATOR
Intervention: Conventional total knee replacement
Number of subjects: 71
Study 15119886 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone graft from mandibular symphysis
Number of subjects: 46
Study 15119886 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone graft from ramus
Number of subjects: 46
Study 15119886 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone graft from tuberosity
Number of subjects: 46
Study 11499504 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-implant overdenture treatment
Number of subjects: 24
Study 11499504 — intervention group
Group type: COMPARATOR
Intervention: Four-implant overdenture treatment
Number of subjects: 24
Study 9576150 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 324
Study 9576150 — intervention group
Group type: EXPERIMENTAL
Intervention: Inogatran
Number of subjects: 324
Study 7889893 — intervention group
Group type: COMPARATOR
Intervention: Mixed oil rich in saturated fatty acids (SFA)
Number of subjects: 12
Study 7889893 — intervention group
Group type: COMPARATOR
Intervention: Corn oil rich in n-6 fatty acids
Number of subjects: 12
Study 7889893 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil concentrate (MaxEPA) rich in n-3 fatty acids
Number of subjects: 12
Study 2466315 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG)
Number of subjects: 6
Study 2466315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29693749 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT)
Number of subjects: 0
Study 29693749 — intervention group
Group type: EXPERIMENTAL
Intervention: Various designs for examining treatment outcomes
Number of subjects: 0
Study 28296730 — intervention group
Group type: EXPERIMENTAL
Intervention: CARE kV technique with SAFIRE reconstruction (value=3)
Number of subjects: 130
Study 28296730 — intervention group
Group type: COMPARATOR
Intervention: 120 kV (control group)
Number of subjects: 130
Study 26311549 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation and biofeedback treatment
Number of subjects: 324
Study 26311549 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscle exercise at home (Control)
Number of subjects: 324
Study 22952402 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-piece MICS IOL (AF-1 NY-60, Hoya)
Number of subjects: 40
Study 22952402 — intervention group
Group type: COMPARATOR
Intervention: 3-piece MICS IOL (AF-1 iMICS Y-60H, Hoya)
Number of subjects: 40
Study 20831669 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% triclosan/2% copolymer dentifrice
Number of subjects: 120
Study 20831669 — intervention group
Group type: COMPARATOR
Intervention: Fluoride dentifrice
Number of subjects: 120
Study 19064823 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 11326
Study 19064823 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol tartrate
Number of subjects: 11326
Study 19064823 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 11326
Study 19064823 — intervention group
Group type: COMPARATOR
Intervention: No β-blockers
Number of subjects: 11326
Study 15964943 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servoventilation (ASV)
Number of subjects: 25
Study 15964943 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 25
Study 12620164 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin 5% cream
Number of subjects: 0
Study 12620164 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole 0.75% gel
Number of subjects: 0
Study 12620164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10698027 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% diclofenac
Number of subjects: 106
Study 10698027 — intervention group
Group type: COMPARATOR
Intervention: 0.1% fluorometholone
Number of subjects: 106
Study 8825812 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 0.4 IU/kg/wk (D1)
Number of subjects: 78
Study 8825812 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 1.2 IU/kg/wk (D2)
Number of subjects: 78
Study 8825812 — intervention group
Group type: COMPARATOR
Intervention: GH 0.4 IU/kg/wk (D1) continued
Number of subjects: 78
Study 8825812 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 0.4 IU/kg/wk (D1) increased to 1.2 IU/kg/wk (D1D2)
Number of subjects: 78
Study 8825812 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 1.2 IU/kg/wk (D2) continued
Number of subjects: 78
Study 8825812 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (D1, D1D2, D2)
Number of subjects: 78
Study 1318486 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (180 micrograms, inhaled)
Number of subjects: 15
Study 1318486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3901864 — intervention group
Group type: EXPERIMENTAL
Intervention: Stainless steel staples
Number of subjects: 195
Study 3901864 — intervention group
Group type: COMPARATOR
Intervention: Polypropylene sutures
Number of subjects: 195
Study 3901864 — intervention group
Group type: COMPARATOR
Intervention: Polyglactin sutures
Number of subjects: 195
Study 30638271 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based behavioral treatment (FBT)
Number of subjects: 150
Study 30638271 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-only variant of FBT (PBT)
Number of subjects: 150
Study 30111467 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 79
Study 30111467 — intervention group
Group type: COMPARATOR
Intervention: Supine positioning
Number of subjects: 79
Study 26340545 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of CD133+ bone marrow stem cells
Number of subjects: 37
Study 26340545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 24268614 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Narrative Therapy (CNT)
Number of subjects: 97
Study 24268614 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐Behavioral Therapy (CBT)
Number of subjects: 97